# REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients

> **NCT01171209** · PHASE2 · COMPLETED · sponsor: **Melinda Magyari** · enrollment: 10 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Interferon-beta and human leukocyte Interferon-α

## Key facts

- **NCT ID:** NCT01171209
- **Lead sponsor:** Melinda Magyari
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-06
- **Final completion:** 2011-08
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2012-11-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01171209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01171209, "REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01171209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*